Position in TRLV
as of Jun 30, 2026
· filed Aug 10, 2026
Position Value
$167,306
New position
Shares Held
17,020
first reported quarter
Ownership
0.009%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#60
of 125 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 50%
Shared 0%
None 50%
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Arax Advisory Partners holds $14,581,452 across 56 Drug Manufacturers - Specialty & Generic names. TRLV ranks #14 (1.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
24,261 | $4,088,948 | |
| 2 | UTHR |
UNITED THERAPEUTICS Corp
|
6,216 | $3,368,015 | |
| 3 | VTRS |
Viatris Inc
|
83,877 | $1,331,966 | |
| 4 | HLN |
Haleon plc
|
81,966 | $764,742 | |
| 5 | TEVA |
Teva Pharmaceutical Industries Ltd
|
21,768 | $737,499 | |
| 6 | ZTS |
Zoetis Inc.
|
9,047 | $650,117 | |
| 7 | TAK |
Takeda Pharmaceutical Co Ltd
|
39,210 | $628,536 | |
| 8 | IRWD |
Ironwood Pharmaceuticals Inc
|
126,966 | $534,526 |
All Filings in TRLV
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $167,306 | 17,020 | Shares | Sole | 2026-08-10 | |
| No filing history on record for this holder in this stock. | ||||||